Categories: Headlines

COVID-19 Vaccine 94.5% Effective, Says Moderna

File photo of a researcher working on the diagnosis of suspected coronavirus COVID-19 cases in Belo Horizonte, state of Minas Gerais, Brazil.  AFP


US biotech firm Moderna on Monday announced its experimental vaccine against Covid-19 was 94.5 per cent effective, marking a second major breakthrough in the vaccine hunt.

Moderna released early results from a clinical trial with more than 30,000 participants, after US pharmaceutical company Pfizer and its German partner BioNTech last week said their vaccine was 90 per cent effective.

Both vaccine frontrunners are based on a new platform called messenger RNA, which is faster to produce than traditional vaccines and effectively turn human cells into vaccine factories.

“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stephane Bancel, Moderna’s CEO.

The company plans to submit applications for emergency approval in the US and around the world within weeks and says it expects to have approximately 20 million doses ready to ship in the US by the end of the year.

Global infections from Covid-19 have soared past 54 million with more than 1.3 million deaths since the virus emerged in China late last year.

The Moderna vaccine, which was co-developed by the US National Institutes of Health, is given in two doses 28 days apart, and the preliminary results are based on 95 volunteers of the 30,000 who fell ill with Covid-19.

Of the 95, 90 had been in the trial’s placebo group, and five in the group that received the drug called mRNA-1273.

 ‘Tremendously exciting’ 

There were 11 people who fell severely ill, all of whom were in the placebo group.

The vaccine was well tolerated, with the majority of side-effects classed as mild or moderate.

After the first dose, about three per cent of people had injection site pain classed as severe.

Among side-effects classed as severe after the second dose, about 10 per cent had fatigue, nine per cent had muscle pain, five per cent had joint pain or headaches, four per cent had other pain and two per cent had redness at the injection site.

These adverse events were “short-lived,” according to a statement.

“This news from Moderna is tremendously exciting and considerably boosts optimism that we will have a choice of good vaccines in the next few months,” said Peter Openshaw, a professor of experimental medicine at Imperial College London.

Crucially, Moderna also announced that its vaccine can remain stable at standard refrigerator temperatures of 2 degrees Celsius to 8 degrees Celsius (36 degrees Fahrenheit to 46 degrees Fahrenheit) for 30 days.

The company added it could be kept in long-term storage at standard freezer temperatures of -20 degrees Celsius (-4 degrees Fahrenheit) for up to six months.

Pfizer’s vaccine, on the other hand, needs to be stored in deep-freezer conditions which could complicate supply chain logistics, particularly in less developed countries.

It is not yet clear how long-lasting the protection will be from either the Moderna or Pfizer vaccines, nor how well they work for the elderly, the age-group at highest risk from Covid-19.


Ignatius Igwe

Disqus Comments Loading...

Recent Posts

  • Politics

INEC Arraigns Professor, Dismisses Three Officials Over Electoral Offences

  The Independent National Electoral Commission (INEC) has arraigned a university professor who served as a collation/returning officer in the…

5 mins ago
  • Coronavirus

100 Pupils Test Positive For COVID-19 In Zimbabwe School

  A hundred students at a high school in northwestern Zimbabwe have tested positive for coronavirus, the government said Tuesday,…

18 mins ago
  • Headlines

Ebonyi Governor, David Umahi, Defects From PDP To APC

  Ebonyi State Governor, David Umahi, has defected from the Peoples Democratic Party (PDP) to the All Progressives Congress (APC).…

1 hour ago
  • Local

Banditry: Senator Condemns Kaduna Killings, Says It’s Time To Take Action

  The Senator representing Kaduna Central in the National Assembly, Uba Sani has condemned the renewed attacks on communities in…

2 hours ago
  • Sports

AFCON Qualifier: Rohr To Start Iheanacho, Etebo, Others Against Sierra Leone

  Super Eagles Coach, Gernot Rohr, has selected Leicester City forward, Kelechi Iheanacho, and Galatasaray midfielder, Peter Etebo, to start…

2 hours ago
  • Sports

Semenya Heads To European Human Rights Court To Overturn Ban

    South Africa's Olympic 800m champion Caster Semenya is taking her battle with World Athletics to the European Court…

2 hours ago